Development · 29 Sep 2026
4 publishers have reported this development. Each act of reporting is below, cited.
Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths.
Morepen Laboratories announced in an exchange filing that it has submitted its first ANDA to the USFDA for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths.
Morepen Laboratories Ltd submitted its first Abbreviated New Drug Application to the US Food and Drug Administration on September 25, 2026, for Sitagliptin Tablets USP in three dosage strengths.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.